Algernon Pharmaceuticals (AGNPF) News Today $0.05 +0.00 (+6.88%) As of 08/28/2025 02:30 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartHeadlinesSEC FilingsShort InterestBuy This Stock AGNPF Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Algernon Pharmaceuticals Amends Private Placement Terms and Closes First TrancheAugust 26 at 4:30 PM | theglobeandmail.comAlgernon Pharmaceuticals closes private placement to fund Alzheimer's clinic initiativeJuly 25, 2025 | proactiveinvestors.comAlgernon Announces Closing of the Private Placement FinancingJuly 24, 2025 | globenewswire.comAlgernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling $621,000June 30, 2025 | globenewswire.comAlgernon Announces $1M Private PlacementMay 27, 2025 | globenewswire.comAlgernon closes NoBrainer acquisitionMay 23, 2025 | msn.comAlgernon Closes NoBrainer Imaging Centers, Inc. AcquisitionMay 22, 2025 | financialpost.comFAlgernon Closes NoBrainer Imaging Centers, Inc. AcquisitionMay 22, 2025 | globenewswire.comAlgernon to Acquire NoBrainer Imaging Centers, Inc. – Plans to Establish Alzheimer’s Diagnostic and Treatment Medical Clinics Featuring New PET Scan TechnologyMay 13, 2025 | financialpost.comFAlgernon to Acquire NoBrainer Imaging Centers, Inc. – Plans to Establish Alzheimer’s Diagnostic and Treatment Medical Clinics Featuring New PET Scan TechnologyMay 13, 2025 | financialpost.comFAlgernon to Acquire NoBrainer Imaging Centers, Inc. - Plans to Establish Alzheimer's Diagnostic and Treatment Medical Clinics Featuring New PET Scan TechnologyMay 13, 2025 | globenewswire.comAlgernon Announces Warrant ExtensionMay 5, 2025 | globenewswire.comAlgernon Pharmaceuticals receives notice of allowance from EPO for RepirinastApril 8, 2025 | markets.businessinsider.comAlgernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney DiseaseApril 8, 2025 | financialpost.comFAlgernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney DiseaseApril 8, 2025 | globenewswire.comAlgernon engages Netcapital Securities for Regulation A financingMarch 6, 2025 | markets.businessinsider.comAlgernon NeuroScience Engages Netcapital Securities for Planned Regulation A FinancingMarch 6, 2025 | financialpost.comFAlgernon NeuroScience Engages Netcapital Securities for Planned Regulation A FinancingMarch 6, 2025 | globenewswire.comAlgernon Pharmaceuticals appoints Sandor Nardai as OI for Phase 2a DMT studyFebruary 11, 2025 | markets.businessinsider.comAlgernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke StudyFebruary 11, 2025 | financialpost.comFAlgernon NeuroScience Appoints Globally Recognized DMT Researcher and Clinician Dr. Sándor Nardai as Principal Investigator for Planned Phase 2a DMT Human Stroke StudyFebruary 11, 2025 | globenewswire.comAlgernon NeuroScience Appoints Validcare as CRO for its Phase 2a DMT Human Stroke Trial and Announces Validcare's USD $170K Equity InvestmentFebruary 5, 2025 | globenewswire.comAlgernon Pharmaceuticals Receives Notice of Allowance from USPTO For Repirinast in Kidney Disease PatentJanuary 6, 2025 | financialpost.comFAlgernon Announces Warrant ExtensionNovember 4, 2024 | globenewswire.comAlgernon Pharmaceuticals Inc. (AGNPF)September 5, 2024 | finance.yahoo.comAlgernon Pharmaceuticals Inc Class AAugust 31, 2024 | morningstar.comMAlgernon Pharmaceuticals Announces Closing of Private PlacementAugust 20, 2024 | globenewswire.comAlgernon Pharmaceuticals Announces Increase to Private PlacementAugust 13, 2024 | globenewswire.comAlgernon Pharmaceuticals Announces Private PlacementAugust 7, 2024 | globenewswire.comAlgernon Pharmaceuticals Announces Closing of Private PlacementAugust 2, 2024 | globenewswire.comAlgernon Pharmaceuticals Announces Increase to Private PlacementJuly 31, 2024 | globenewswire.comAlgernon Pharmaceuticals Announces Private PlacementJuly 11, 2024 | globenewswire.comAlgernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making ServicesMay 21, 2024 | globenewswire.comAlgernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024April 24, 2024 | globenewswire.comAlgernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024April 11, 2024 | globenewswire.comDMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial DesignApril 3, 2024 | msn.comAlgernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead AssetApril 1, 2024 | globenewswire.comAlgernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough TreatmentMarch 28, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - AGNMarch 27, 2024 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - AGNMarch 27, 2024 | finance.yahoo.comAlgernon Pharmaceuticals closes $2M acquisition of its chronic cough research program by SeyltxMarch 27, 2024 | proactiveinvestors.comAlgernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity PositionMarch 27, 2024 | globenewswire.comAlgernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKDJanuary 31, 2024 | finance.yahoo.comAlgernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent in Japan for Idiopathic Pulmonary FibrosisJanuary 11, 2024 | finance.yahoo.comAlgernon Pharmaceuticals Announces Increase to Private PlacementDecember 27, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLDNovember 30, 2023 | finance.yahoo.comSeyltx acquires Algernon's chronic cough research program for $2M and 20% stakeNovember 22, 2023 | msn.comAlgernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity PositionNovember 22, 2023 | finance.yahoo.comAlgernon Pharmaceuticals Inc. (AGN.CN)November 12, 2023 | uk.finance.yahoo.comAlgernon gets Japanese patent notice of allowance for treatment of NASH with RepirinastNovember 8, 2023 | msn.com Get Algernon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGNPF and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AGNPF Media Mentions By Week AGNPF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AGNPF News Sentiment▼0.001.03▲Average Medical News Sentiment AGNPF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AGNPF Articles This Week▼10▲AGNPF Articles Average Week Get the Latest News and Ratings for AGNPF and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Algernon Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies 4Front Ventures News Today Ainos News Today Allstar Health Brands News Today AstraZeneca News Today AVAX Technologies News Today BriaCell Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:AGNPF) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Algernon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Algernon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access